LumiraDx Receives FDA EUA for its COVID-19 Antibody Test
LumiraDx has announced receiving FDA EUA for its SARS-CoV-2 Ab test, which is used to help identify an adaptive immune response to SARS-CoV-2.
Read MorePosted by Chris Wolski | Aug 5, 2021 | Covid 19, POC Rapid Assays |
LumiraDx has announced receiving FDA EUA for its SARS-CoV-2 Ab test, which is used to help identify an adaptive immune response to SARS-CoV-2.
Read MorePosted by Chris Wolski | Aug 5, 2021 | Sexually Transmitted Diseases |
Hologic, Inc. has commended the decision of the CDC to endorse an updated approach to screening for two of the most common STIs in the U.S.
Read MorePosted by Chris Wolski | Aug 3, 2021 | Information Technology |
LigoLab Information System has announced that its TestDirectly patient platform supports laboratory services being provided in the home.
Read MorePosted by Chris Wolski | Jul 20, 2021 | Diagnostic Technologies, Point-of-Care |
Matrix Clinical Care has expanded its set of in-home testing and diagnostic capabilities to meet increasing demand for in-home healthcare.
Read MorePosted by Chris Wolski | Jul 14, 2021 | Covid 19, POC Rapid Assays, Rapid Assays, Sepsis, Stroke |
NanoDx, Inc., has entered into a licensing agreement with IBM Research for use of its nanoscale sensors for accurate, rapid testing.
Read More